Advances of Molecular Targeted Therapy in Gastric Cancer

Journal of Gastrointestinal Cancer

Volumn 47, Issue 2, 2016, Pages 125-134

  Cetin, Bulent ^a   Gumusay, Ozge ^b   Cengiz, Mustafa ^c   Ozet, Ahmet ^d  

^a CUMHURIYET UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^b GAZIOSMANPASA UNIVERSITY   (Turkey)

^c Dr Abdurrahman Yurtaslan Oncology Training and Research Hospital   (Turkey)

^d GAZI UNIVERSITY FACULTY OF MEDICINE   (Turkey)

Author keywords

Gastric cancer; Metastatic disease; Molecular biology; New drugs; Targeted drugs

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CABOZANTINIB; CAPECITABINE; CETUXIMAB; CISPLATIN; CRIZOTINIB; DOCETAXEL; EPIRUBICIN; EVEROLIMUS; FICLATUZUMAB; FLUOROPYRIMIDINE; FLUOROURACIL; FORETINIB; IRINOTECAN; LAPATINIB; ONARTUZUMAB; OXALIPLATIN; PACLITAXEL; PANITUMUMAB; PERTUZUMAB; PLACEBO; RAMUCIRUMAB; RILOTUMUMAB; SUNITINIB; TAK 701; TIVANTINIB; TRASTUZUMAB; TRASTUZUMAB EMTANSINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADENOCARCINOMA; ADVANCED CANCER; ARTERIAL THROMBOEMBOLISM; CANCER GROWTH; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; EPITHELIAL MESENCHYMAL TRANSITION; FISTULA; GASTROESOPHAGEAL ADENOCARCINOMA; GASTROESOPHAGEAL CANCER; HAND FOOT SYNDROME; HEART FAILURE; HUMAN; HYPERTENSION; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; SIGNAL TRANSDUCTION; STOMACH CANCER; TREATMENT RESPONSE; VENOUS THROMBOEMBOLISM; PROCEDURES; STOMACH NEOPLASMS;

HUMANS; MOLECULAR TARGETED THERAPY; STOMACH NEOPLASMS;

EID: 84957947280     PISSN: 19416628     EISSN: 19416636     Source Type: Journal    
DOI: 10.1007/s12029-016-9806-8     Document Type: Review

References (62)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64:9–29.
2. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.
3. Anderson WF, Camargo MC, Fraumeni Jr JF, et al. Age-specific trends in incidence of noncardia gastric cancer in US adults. JAMA. 2010;303:1723–28.
4. Graham DY, Asaka M. Eradication of gastric cancer and more efficient gastric cancer surveillance in Japan: two peas in a pod. J Gastroenterol. 2010;45:1–8.
5. Pfeifer JD. Molecular genetic testing in surgical pathology. Philadelphia: Lippincott Williams & Wilkins; 2006.
6. Souza RF, Spechler SJ. Concepts in the prevention of adenocarcinoma of the distal esophagus and proximal stomach. CA Cancer J Clin. 2005;55:334–51.
7. DeVita, Hellman, and Rosenberg’s Cancer: Principles @ Practice of Oncology, 10e, 2015.
8. Jinawath N, Furukawa Y, Hasegawa S, et al. Comparison of gene-expression profiles between diffuse- and intestinal-type gastric cancers using a genome-wide cDNA microarray. Oncogene. 2004;23:6830–44.
9. Yokota J, Yamamoto T, Toyoshima K, et al. Amplification of c-erbB-2 oncogene in human adenocarcinomas in vivo. Lancet. 1986;1:765–67.
10. Janjigian YY, Tang LH, Coit DG, et al. MET expression and amplification in patients with localized gastric cancer. Cancer Epidemiol Biomarkers Prev. 2011;20:1021–27.
11. Lee J, Seo JW, Jun HJ, et al. Impact of MET amplification on gastric cancer: possible roles as a novel prognostic marker and a potential therapeutic target. Oncol Rep. 2011;25:1517–24.
12. Lennerz JK, Kwak EL, Ackerman A, et al. MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. J Clin Oncol. 2011;29:4803–10.
13. Corso S, Ghiso E, Cepero V, et al. Activation of HER family members in gastric carcinoma cells mediates resistance to MET inhibition. Mol Cancer. 2010;9:121.
14. Yokozaki H, Yasui W, Tahara E. Genetic and epigenetic changes in stomach cancer. Int Rev Cytol. 2001;204:49–95.
15. Liu Z, Liu L, Li M, et al. Epidermal growth factor receptor mutation in gastric cancer. Pathology. 2011;43:234–38.
16. Mammano E, Belluco C, Sciro M, et al. Epidermal growth factor receptor (EGFR): mutational and protein expression analysis in gastric cancer. Anticancer Res. 2006;26:3547–50.
17. Song S, Ajani JA. The role of microRNAs in cancers of the upper gastrointestinal tract. Nat Rev Gastroenterol Hepatol. 2013;10:109–18.
18. Hattori Y, Itoh H, Uchino S, et al. Immunohistochemical detection of K-sam protein in stomach cancer. Clin Cancer Res. 1996;2:1373–81.
19. Yu G, Wang J, Chen Y, et al. Overexpression of phosphorylated mammalian target of rapamycin predicts lymph node metastasis and prognosis of Chinese patients with gastric cancer. Clin Cancer Res. 2009;15:1821–29.
20. Lang SA, Gaumann A, Koehl GE, et al. Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model. Int J Cancer. 2007;120:1803–10.
21. Komuro A, Yashiro M, Iwata C, et al. Diffuse-type gastric carcinoma: progression, angiogenesis, and transforming growth factor β signaling. J Natl Cancer Inst. 2009;101:592–604.
22. Kobayashi M, Kawashima A, Mai M, et al. Analysis of chromosome 17p3 (p53 locus) alterations in gastric carcinoma cells by dual-color fluorescence in situ hybridization. Am J Pathol. 1996;149:1575–84.
23. Takahashi Y, Cleary KR, Mai M, et al. Significance of vessel count and vascular endothelial growth factor and its receptor (KDR) in intestinal-type gastric cancer. Clin Cancer Res. 1996;2:1679–84.
24. Wong H, Yau T. Targeted therapy in the management of advanced gastric cancer: are we making progress in the era of personalized medicine? Oncologist. 2012;17:346–58.
25. Pereira PS, Teixeira A, Pinho S, et al. E-cadherin missense mutations, associated with hereditary diffuse gastric cancer (HDGC) syndrome, display distinct invasive behaviors and genetic interactions with the Wnt and Notch pathways in Drosophila epithelia. Hum Mol Genet. 2006;15:1704–12.
26. Shimada S, Mimata A, Sekine M, et al. Synergistic tumour suppressor activity of E-cadherin and p53 in a conditional mouse model for metastatic diffuse-type gastric cancer. Gut. 2012;61(3):344–53.
27. Sereno M, Aguayo C, Guillén Ponce C, et al. Gastric tumours in hereditary cancer syndromes: clinical features, molecular biology and strategies for prevention. Clin Transl Oncol. 2011;13:599–610.
28. Figueiredo J, Simões-Correia J, Söderberg O, et al. ADP-ribosylation factor 6 mediates E-cadherin recovery by chemical chaperones. PLoS One. 2011;6(8):e23188.
29. Shah MA, Salo-Mullen E, Stadler Z, et al. De novo CDH1 mutation in a family presenting with early-onset diffuse gastric cancer. Clin Genet. 2012;82(3):283–87.
30. Kluijt I, Siemerink EJ, Ausems MG, et al. Dutch Working Group on Hereditary Gastric Cancer. CDH1-related hereditary diffuse gastric cancer syndrome: clinical variations and implications for counseling. Int J Cancer. 2012;131(2):367–76.
31. Becker KF, Atkinson MJ, Reich U, et al. E-cadherin gene mutations provide clues to diffuse type gastric carcinomas. Cancer Res. 1994;54:3845–52.
32. Grunwald GB. The structural and functional analysis of cadherin calcium-dependent cell adhesion molecules. Curr Opin Cell Biol. 1993;5:797–805.
33. Birchmeier W. E-cadherin as a tumor (invasion) suppressor gene. Bioessays. 1995;17:97–9.
34. Wu K, Nie Y, Guo C, et al. Molecular basis of therapeutic approaches to gastric cancer. J Gastroenterol Hepatol. 2009;24(1):37–41.
35. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer. 2005;5:341–54.
36. Waddell T, Chau I, Cunningham D, et al. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomized, open-label phase 3 trial. Lancet Oncol. 2013;14:481–89.
37. Lordick F, Kang YK, Chung HC, Arbeitsgemeinschaft Internistische Onkologie and EXPAND Investigators, et al. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomized, open-label phase 3 trial. Lancet Oncol. 2013;14(6):490–99.
38. Bang YJ, Van Cutsem E, Feyereislova A, ToGA Trial Investigators, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;28(376(9742)):687–97.
39. Hecht JR, Bang YJ, Qin S, et al. Lapatinib in combination with capecitabine plus oxaliplatin (CapeOx) in HER2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma (AC): the TRIO-013/LOGiC Trial. J Clin Oncol. 31, 2013 (suppl; abstr LBA4001). ASCO 2013. Abstract number: LBA4001
40. A study of trastuzumab emtansine versus taxane in patients with advanced gastric cancer. Available from: Clin Trials.gov. NCT01641939. Accessed
41. Ohtsu A, Shah MA, Van Cutsem E, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol. 2011;29:3968–76.
42. Tabernero J, Tomasek J, Filip D, et al. REGARD phase 3, randomized trial of ramucirumab in patients with metastatic gastric or GEJ adenocarcinoma following progression on first-line chemotherapy. Ann Oncol. 2013;24 suppl 4:iv14.
43. Fuchs CS, Tomasek J, Yong CJ, REGARD Trial Investigators, et al. Ramucirumab monotherapy for previously treated advanced gastric or Gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2014;383:31–9.
44. http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm394107.htm.
45. Wilek H, Cutsem EV, Oh SC, et al. RAINBOW: a global, phase III, randomized, double-blind study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in the treatment of metastatic gastroesophageal junction (GEJ) and gastric adenocarcinoma following disease progression on first-line platinum-and fluoropyrimidine-containing combination therapy rainbow IMCL CP12-0922 (I4T-IE-JVBE). J Clin Oncol 2014;32 (suppl 3; abstr LBA7).
46. http://www.fda.gov/drugs/informationdrugs/approveddrugs/ucm421930.htm.
47. First-line treatment for locally advanced or metastatic mesenchymal epithelial transition factor (MET)-positive gastric, lower esophageal, or gastroesophageal junction (GEJ) adenocarcinoma (RILOMET-1). Available from: Clin Trials.gov. NCT01697072. Accessed 10 Sept 2014.
48. A Study of Onartuzumab (MetMAb) in combination with mFOLFOX6 in patients with metastatic HER2-negative and met-positive gastroesophageal cancer (MetGastric). Available from: Clin Trials.gov. NCT01662869. Accessed 10 Sept 2014.
49. Byun DS, Cho K, Ryu BK, et al. Frequent monoallelic deletion of PTEN and its reciprocal association with PIK3CA amplification in gastric carcinoma. Int J Cancer. 2003;104:318–27.
50. Oki E, Kakeji Y, Tokunaga E, et al. Impact of PTEN/AKT/PI3K signal pathway on the chemotherapy for gastric cancer [abstract 4034]. J Clin Oncol. 2006;24 Suppl 18:187s.
51. Ohtsu A, Ajani JA, Bai YX, et al. Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study. J Clin Oncol. 2013;31:3935.
52. Lee SH, Lee JW, Soung YH, et al. BRAF and KRAS mutations in stomach cancer. Oncogene. 2003;22:6942–45.
53. Hiyama T, Haruma K, Kitadai Y, et al. K-ras mutation in Helicobacter pylori-associated chronic gastritis in patients with and without gastric cancer. Int J Cancer. 2002;97:562–66.
54. Kim IJ, Park JH, Kang HC, et al. Mutational analysis of BRAF and K-ras in gastric cancers: absence of BRAF mutations in gastric cancers. Hum Genet. 2003;114:18–20.
55. Lee KH, Lee JS, Suh C, et al. Clinicopathologic significance of the K-ras gene codon 12 point mutation in stomach cancer. An analysis of 140 cases. Cancer. 1995;75:2794–801.
56. Nanus DM, Kelsen DP, Mentle IR, et al. Infrequent point mutations of ras oncogenes in gastric cancers. Gastroenterology. 1990;98:955–60.
57. Hongyo T, Buzard GS, Palli D, et al. Mutations of the K-ras and p53 genes in gastric adenocarcinomas from a high-incidence region around Florence, Italy. Cancer Res. 1995;55:2665–72.
58. Sun W, Powell M, O’Dwyer PJ, et al. Phase II study of Sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203. J Clin Oncol. 2010;28:2947–51.
59. Martin J, Donnelly JM, Houghton J, et al. The role of sonic hedgehog reemergence during gastric cancer. Dig Dis Sci. 2010;55:1516–24. doi:10.1007/s10620-010-1252-z.
60. Cohen DJ. Vismodegib (V), a hedgehog (HH) pathway inhibitor combined with FOLFOX for first-line therapy of patients (pts) with advanced gastric and gastroesophageal junction (GJ) carcinoma: A New York cancer consortium led phase II randomized study. J Clin Oncol. 2013;31(suppl):245s. Abstract 4011.
61. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252–64.
62. Muro K, Bang Y-J, Shankaran V, et al. Relationship between PD-L1 expression and clinical outcomes in patients with advanced gastric cancer treated with the anti-PD-1 monoclonal antibody pembrolizumab in KEYNOTE-012 (abstract). J Clin Oncol 2015;33 (suppl 3; abstr 3).